Founded by MedicxiwithGeorgia Tech and UMass scientists, supported byUS $30M investment from Medicxi
Developing advanced, long-lasting therapies for dermatological diseases through radical new transepidermal delivery of proprietary siRNAs
Led by dermatology veteran Thibaud Portal as CEOwith a Scientific Advisory Board chaired by Nobel Prize Laureate, Craig Mello
BOSTON, March 16, 2023 /PRNewswire/ -- Aldena Therapeutics Inc. (Aldena) a private biotech company pioneering siRNA-based therapies for dermatological indications, announces an update on its innovative, immuno-dermatology pipeline, appointment of world leading Scientific Advisory Board (SAB) and US$ 30 million financing by Medicxi.
Under the leadership of CEO, dermatology industry veteran Thibaud Portal, Aldena's goal is to develop advanced, long-lasting treatments for dermatological diseases based on its disruptive approach to immuno-dermatology. The company's technology has the potential to capture the full value of systemically validated Mode of Actions (MOA) through radical new transepidermal delivery of proprietary siRNAs.
Aldena was co-founded by Professor John Harris (MD, PhD, Professor and Chair of Dermatology at UMass Chan Medical School), Professor Mark Prausnitz (PhD, Regents' Professor at Georgia Institute of Technology) and Dr Andrew Tadros (MD, PhD) and backed by Medicxi.
Craig Mello, PhD, the Physiology and Medicine Nobel Prize Laureate will Chair the SAB, alongside specialists in the field of dermatology; Lars French, MD, PhD, Jonathan Silverberg, MD, PhD, MPH and Anastasia Khvorova, PhD, who will join founding advisors John Harris, MD, PhD and Mark Prausnitz, PhD on the SAB as core experts to serve as its strategic resource to establish Aldena's efforts to expand its innovative, pipeline of Dermatology products.
Aldena has a pipelineof six different compounds, three of which will be ready forIND filing next year. Theinnovative pipeline of dermatological siRNA therapies are targeting the unmet medical need in conditions like Atopic Dermatitis, Vitiligo, Alopecia Areata, Psoriasis and other inflammatory diseases.
Story continues
Thibaud Portal, Chief Executive Officer of Aldena Therapeutics, said:"I am delighted to reveal Aldena Therapeutics as we accelerate our mission to develop an innovative pipeline of dermatological siRNA therapies that have the potential to transform the treatment of multiple dermatological diseases. I am honored to have such world leaders in the scientific and medical fields on our scientific advisory board which is significant validation of our approach. Their deep and diverse expertise across the fields of siRNA research and development, of advanced drug delivery solutions and of development of groundbreaking dermatologic products, will be immensely valuable as we continue to advance our pipeline."
Craig Mello, Chair of Aldena Therapeutics Scientific Advisory Board, commented: "The most influential way to make a lasting impact in the life science community is to create pioneering, effective products that address the unmet medical need of patients. I am delighted to chair this multidisciplinary and highly experienced Scientific Advisory Board, where engineers, scientists, and medical professionals come together to develop innovative, dermatological products for the benefit of millions of patients."
Francesco De Rubertis, co-founder and Partner at Medicxi, member of the Board of Directors of Aldena, added: "We are delighted to collaborate with leading scientists from Georgia Tech and UMass to create Aldena Therapeutics, a company based on its truly disruptive approach to immuno-dermatology. Aldena brings together a phenomenal team of leaders with expert knowledge to develop transformative and long-lasting therapies for many dermatology diseases."
Scientific Advisory Board
Prof. Craig C. Mello:is an Investigator at the Howard Hughes Medical Institute, the Blais University Chair in Molecular Medicine, and co-director of the RNA Therapeutics Institute at the University of Massachusetts Chan Medical School (UMCMS). His research is aimed at deciphering the molecular mechanisms underlying small-RNA-silencing in C Elegans to inform the understanding of human health and disease. Prof. Mello was a co-recipient, with Andrew Z. Fire, of the Nobel Prize for Physiology and Medicine in 2006 for discovering RNA interference (RNAi), a mechanism that regulates gene activity. In addition, Prof. Mello received the 2003 Wiley Prize, the 2003 National Academy of Sciences Award in Molecular Biology, the 2004 Warren Triennial Prize, the 2005 Canada Gairdner International Award, the 2005 Massry Prize and was also awarded the title of Howard Hughes Medical Investigator for his significant contributions to science.
Dr. Med. Lars E French:is a professor and chairman of the Department of Dermatology at the Munich University of Ludwig Maximilian (LMU) in Germany. Professor French is a clinician and a scientist engaged in competitive research and development in the field of inflammatory skin disease and tumour immunology. In 2012, Professor French was awarded the Otto Naegeli Prize for the promotion of medical research, one of Switzerland's most prestigious scientific awards.
Dr. Jonathan Silverberg:is an Associate Professor of Dermatology at The George Washington University School of Medicine and Health Sciences in Washington, DC. He is the Director of Clinical Research and Contact Dermatitis. Dr. Silverberg's area of clinical subspecialty is inflammatory skin diseases, and research interests include drug development, clinical trial design, biomarkers, dermato-epidemiology, health services research, patient-reported outcomes, comorbidities and burden of itch and inflammatory skin disease and evidence-based dermatology. He has been recognized with several honours, including the Young Leadership Award from the American Dermatological Association in 2017, Teacher of the Year Award in the department of dermatology in 2015, Outstanding Teacher's Award from the Feinberg School of Medicine in 2016, 2017 and 2018, and the inaugural Rajka Award from the International Society for Atopic Dermatitis in 2014.
Dr. Anastasia Khvorova:has more than 20 years of experience developing oligonucleotide technology and therapeutics. She is a professor in the RNA Therapeutics Institute and Program of Molecular Medicine at the University of Massachusetts Chan Medical School (UMCMS), where her lab develops novel approaches and solutions to understanding natural and therapeutic RNA trafficking and delivery. Dr. Khvorova founded the UMass Nucleic Acid Chemistry Core after several years in industry, during which she served as Chief Scientific Officer (CSO) at leading biotech companies and co-founded several start-ups.
Scientists and academic collaborators of Aldena will be presenting at the upcoming Dermatology Innovation Forum in New Orleans on March 16th 2023, and at the first International Societies for Investigative Dermatology Meeting in Tokyo, 1-13 May 2023.
About AldenaAldena Therapeutics is a Boston, Lausanne and London-based biotechnology company focusing on siRNA-based treatments for patients suffering from dermatological diseases. The Company was co-founded by Prof. John Harris (MD, PhD, Professor and Chair of Dermatology at UMass Chan Medical School), Prof. Mark Prausnitz (PhD, Regents' Professor at Georgia Institute of Technology) and Dr Andrew Tadros (MD, PhD) and is backed by international investment firm, Medicxi. Aldena Therapeutics has been led since its inception by dermatology specialist, CEO, Thibaud Portal, PhD, who previously led the Prescription Medicines business and strategy of Galderma SA after several senior R&D roles and co-founded several dermatology focused start-up companies. Aldena is pursuing multiple innovative programs and is currently initiating the IND-enabling GLP nonclinical program for its lead projects.
About MedicxiMedicxi is a healthcare-focused investment firm with the mission to create and invest in companies across the full drug development continuum. Leveraging deep expertise in drug development and company creation spanning over two decades, Medicxi invests in early and late-stage therapeutics with a product vision that can fulfill a clear unmet medical need. For more information, please visit: https://www.medicxi.com
Cision
View original content:https://www.prnewswire.com/news-releases/aldena-therapeutics-accelerates-its-novel-and-disruptive-approach-to-immuno-dermatology-301773160.html
SOURCE Aldena Therapeutics
See the rest here:
- Advancing Hidradenitis Suppurativa Care - Early Diagnosis, Biologic Therapies, and Multidisciplinary Approaches: Part 3 - Dermatology Times - March 30th, 2025 [March 30th, 2025]
- Top 5 Articles of the Month: March - Dermatology Times - March 30th, 2025 [March 30th, 2025]
- Talking to Patients on Sunscreen Application and the Effects of Visible Light - Dermatology Times - March 30th, 2025 [March 30th, 2025]
- Challenges and Unmet Needs in Treating Pediatric Atopic Dermatitis - Dermatology Times - March 30th, 2025 [March 30th, 2025]
- Clinical Experience and Diagnosis of GPP - Dermatology Times - March 30th, 2025 [March 30th, 2025]
- Gene Expression Profiling and Other Molecular Tests Utilized for Melanoma and Squamous Cell Carcinoma - Dermatology Times - March 30th, 2025 [March 30th, 2025]
- Fixed-Dose Acne Treatment Gel is Safe and Effective for Hispanic Patients, According to Post-Hoc Analysis - Dermatology Times - March 30th, 2025 [March 30th, 2025]
- CBD and CBG Ointment Improved Skin in Patients with Atopic Dermatitis - Dermatology Times - March 30th, 2025 [March 30th, 2025]
- Utilizing Gene Expression Profiling to Avoid Unnecessary Interventions in a 72-Year-Old Woman With Melanoma - Dermatology Times - March 30th, 2025 [March 30th, 2025]
- Hims & Hers shutters Apostrophe in favor of its own tele-dermatology offerings - Fierce healthcare - March 15th, 2025 [March 15th, 2025]
- Closing Out AAD With Dermatology Times Editor in Chief - Dermatology Times - March 15th, 2025 [March 15th, 2025]
- Improving Patient Care in Dermatology Through Data, Innovation, Advocacy: AAD 2025 Recap - AJMC.com Managed Markets Network - March 15th, 2025 [March 15th, 2025]
- Inflammatory Arthropathy Risk Increased in Patients With Hidradenitis Suppurativa - Dermatology Advisor - March 15th, 2025 [March 15th, 2025]
- Expert Perspectives: Dermatology's Top Story to Watch in 2025 - MD Magazine - March 15th, 2025 [March 15th, 2025]
- Whats New in Dermatology for Pigmentary Disorders, with Andrew Alexis, MD, MPH - MD Magazine - March 15th, 2025 [March 15th, 2025]
- Home Phototherapy Proves Effective and Preferred in LITE Study for Psoriasis Treatment - Dermatology Times - March 15th, 2025 [March 15th, 2025]
- Efficacy, Safety, and Role in Therapy of JAK Inhibitors for Atopic Dermatitis - Dermatology Times - March 15th, 2025 [March 15th, 2025]
- Reviving the Classics: The Role of Older Medications in Modern Dermatology - AJMC.com Managed Markets Network - March 15th, 2025 [March 15th, 2025]
- Dermatology Therapeutics: Updates for Primary Care from AAD 2025 - Patient Care Online - March 15th, 2025 [March 15th, 2025]
- Advances in Dermatology Therapeutics: Key Insights from AAD 2025 - Patient Care Online - March 15th, 2025 [March 15th, 2025]
- The Impact of JAK Selectivity in Atopic Dermatitis Treatment - Dermatology Times - March 15th, 2025 [March 15th, 2025]
- Social Drivers of Health Success Stories in Dermatology | AAD 2025 - Managed Healthcare Executive - March 15th, 2025 [March 15th, 2025]
- Improving Acne Treatment Through Antibiotic Stewardship and Gut-Skin Health - Dermatology Times - March 15th, 2025 [March 15th, 2025]
- Advancing Recognition and Treatment of Allergic Contact Dermatitis - Dermatology Times - March 15th, 2025 [March 15th, 2025]
- Lebrikizumab Shows 3-Year Sustained Efficacy in AD - Dermatology Times - March 15th, 2025 [March 15th, 2025]
- AAD 2025: Galderma to Present Extensive Updates From Across Its Dermatology Portfolio, Demonstrating Its Category Leadership and Strong Momentum -... - March 5th, 2025 [March 5th, 2025]
- What to Look Forward to at the American Academy of Dermatology Annual Meeting 2025 - MD Magazine - March 5th, 2025 [March 5th, 2025]
- Recognizing the Achievements of Women in Dermatology - Dermatology Times - March 5th, 2025 [March 5th, 2025]
- The Solar Spectrum and Impact on Skin Health - Dermatology Times - March 5th, 2025 [March 5th, 2025]
- The Undetectable Era: How Patients Are Shifting Towards More Natural-Looking Results at the Clinic - Dermatology Times - March 5th, 2025 [March 5th, 2025]
- Researchers overseas: Radiology has become indispensable to dermatology - Radiology Business - March 5th, 2025 [March 5th, 2025]
- Defining Alopecia Areata Severity and Navigating Treatment Options - Dermatology Times - March 5th, 2025 [March 5th, 2025]
- Acne and TikTok: What Do Dermatologists Need to Know? - Dermatology Times - March 5th, 2025 [March 5th, 2025]
- Celebrating Womens History Month with Mindy Haws, MD, and the LIMITLESS Initiative - Dermatology Times - March 5th, 2025 [March 5th, 2025]
- A Case-Based Approach to Topical and Nonsteroidal AD Management - Dermatology Times - March 5th, 2025 [March 5th, 2025]
- Dermatology Partners Opens State-of-the-Art Dermatopathology Laboratory - citybiz - February 25th, 2025 [February 25th, 2025]
- Ethical Considerations and Guidance of Cosmeceuticals in Pediatric Care - Dermatology Times - February 25th, 2025 [February 25th, 2025]
- AI in Dermatology: Emerging Insights and Diverging Perspectives - MD Magazine - February 25th, 2025 [February 25th, 2025]
- Almirall 2024 Full-Year Results: Almirall Surpassed Guidance for 2024 - Entering an Era of Sustained Growth and Further Advancing Its Medical... - February 25th, 2025 [February 25th, 2025]
- Aesthetic Treatments: More Than Just Enhancements, A Path to Empowerment - Dermatology Times - February 25th, 2025 [February 25th, 2025]
- Samitivej to advance dermatology and aesthetic medicine in new partnership - Healthcare Asia - February 25th, 2025 [February 25th, 2025]
- Arcutis Announces Publication of Positive Data from INTEGUMENT-PED Trial Evaluating ZORYVE (roflumilast) Cream 0.05% in Children 2 to 5 Years Old with... - February 25th, 2025 [February 25th, 2025]
- U.S. Dermatology Partners Ranked the No. 1 Dermatology Group in the Nation by Castle Connolly - PR Newswire - February 3rd, 2025 [February 3rd, 2025]
- Alopecia Areata Risk May be Associated With Serum Vitamin D and Zinc Levels - Dermatology Advisor - February 3rd, 2025 [February 3rd, 2025]
- Age at Melanoma Diagnosis Varies by Sex, Anatomic Site, and Tumor Thickness - Dermatology Advisor - February 3rd, 2025 [February 3rd, 2025]
- Dermatology Medications and Solutions Market Poised to Growth USD 51.7 Billion by 2032 with Thriving CAGR of - EIN News - January 23rd, 2025 [January 23rd, 2025]
- Optimizing Care for Patients with Urticaria - Dermatology Times - January 23rd, 2025 [January 23rd, 2025]
- Advancing Care With Laser and Light-Based Technology in Dermatology - Dermatology Times - January 23rd, 2025 [January 23rd, 2025]
- Online Dermatology Consultation Market: CAGR of 15.4% Expected by 2025 Due to Increasing Skin Health Awareness - openPR - January 23rd, 2025 [January 23rd, 2025]
- VP-315 Demonstrates Positive Topline Results in Basal Cell Carcinoma - Dermatology Times - January 23rd, 2025 [January 23rd, 2025]
- AI and the Future of Cosmetic Dermatology: Experts Weigh in - Medscape - January 23rd, 2025 [January 23rd, 2025]
- When and How to Employ the Buy and Bill Model - Dermatology Times - January 23rd, 2025 [January 23rd, 2025]
- Innovating Scalp Care: How Research and Education Drive Solutions - Dermatology Times - January 15th, 2025 [January 15th, 2025]
- Rare Overlap of 2 Autoinflammatory Keratinization Diseases Observed in Single Lesion - Dermatology Times - January 15th, 2025 [January 15th, 2025]
- Expanding Laser Benefits for Diverse Patient Populations - Dermatology Times - January 15th, 2025 [January 15th, 2025]
- LEO Pharma and Gilead Will Develop STAT6 Program for AD and Other Inflammatory Diseases - Dermatology Times - January 15th, 2025 [January 15th, 2025]
- Kwon Min-ah, a former member of the group AOA, became the head of the dermatology consultation offic.. - - January 15th, 2025 [January 15th, 2025]
- Top 5 Dermatology Articles of 2024 - Managed Healthcare Executive - January 1st, 2025 [January 1st, 2025]
- DEI programs, sun safety: Read this years top practice management articles in dermatology - Healio - January 1st, 2025 [January 1st, 2025]
- Cutaneous Connection 2024: Top Dermatology Podcast Episodes and Insights of the Year - Dermatology Times - January 1st, 2025 [January 1st, 2025]
- Top Insights and Highlights from Dermatology Times' Interview Intersection: 2024 - Dermatology Times - January 1st, 2025 [January 1st, 2025]
- Providing Support for Comorbidities and Psychological Health in Patients with Atopic Dermatitis - Dermatology Times - January 1st, 2025 [January 1st, 2025]
- Reviewing Major Dermatologic Studies of the Year: 2024 - Dermatology Times - January 1st, 2025 [January 1st, 2025]
- Peak Dermatology in Visalia hopes to provide more skin services and treatment to the area - KFSN-TV - December 23rd, 2024 [December 23rd, 2024]
- Krystal Tawney of Pinnacle Dermatology celebrates 10 years of business in the Greenbrier Valley - Real WV - December 23rd, 2024 [December 23rd, 2024]
- Supporting Pediatric Patients With AD and Their Caregivers - Dermatology Times - December 23rd, 2024 [December 23rd, 2024]
- Photodynamic Therapy is an Effective, Long-Term Treatment for Actinic Keratosis - Dermatology Times - December 23rd, 2024 [December 23rd, 2024]
- InflaRx Advances INF904 for CSU and HS with Phase 2a Study - Dermatology Times - December 23rd, 2024 [December 23rd, 2024]
- Advanced Dermatology to pay $15G fine after doctor refused to perform procedure on HIV-infected patient - Newsday - December 9th, 2024 [December 9th, 2024]
- Efficacy of Combining Postbiotic Formulation with Microneedling for Acne - Dermatology Times - December 9th, 2024 [December 9th, 2024]
- Burden of Hidradenitis Suppurativa on Patients and Diagnostic Challenges - Dermatology Times - December 9th, 2024 [December 9th, 2024]
- Opioid-Prescribing Trends in Dermatology From 2014 to 2020 in the United States - Cureus - November 28th, 2024 [November 28th, 2024]
- Amid challenges, the Baton Rouge dermatology industry is evolving - Greater Baton Rouge Business Report - November 28th, 2024 [November 28th, 2024]
- Polynucleotide Therapy Shows Promise in Scar and Burn Management - Dermatology Times - November 28th, 2024 [November 28th, 2024]
- Revolutionizing Dermatology: How Emerging Technologies are Shaping the Future of Skin Care - Spherical Insights - November 28th, 2024 [November 28th, 2024]
- Dermatology OTC Medications Market Size, Scope Analysis, Key Insights, Leading Key Players, And Forecast To 2033 - openPR - November 28th, 2024 [November 28th, 2024]
- Jeff Stark, MD: Insights on the Approval of Bimekizumab for HS - Dermatology Times - November 28th, 2024 [November 28th, 2024]
- Exploring the Atopic Dermatitis Treatment Paradigm and Challenging Cases: Part 2 - Dermatology Times - November 28th, 2024 [November 28th, 2024]
- Patient Education and Novel Topical Therapies for AD - Dermatology Times - November 28th, 2024 [November 28th, 2024]
- TikTok dermfluencers have medical students flocking to dermatology, where they can make half a million dollars a year and work four days a week -... - November 20th, 2024 [November 20th, 2024]